Icatibant for patients with type III hereditary angioedema a review of clinical effectiveness and harms
Icatibant, a selective bradykinin B2 receptor antagonist, has been approved in many countries worldwide for the symptomatic treatment of acute attacks of types I and II hereditary angioedema (HAE) in adults since 2008. It was reported that icatibant was successful in the prevention of angioedema aft...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa]
Canadian Agency for Drugs and Technologies in Health
February 6, 2014, 2014
|
| Series: | Rapid response report : summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Icatibant, a selective bradykinin B2 receptor antagonist, has been approved in many countries worldwide for the symptomatic treatment of acute attacks of types I and II hereditary angioedema (HAE) in adults since 2008. It was reported that icatibant was successful in the prevention of angioedema after thyroid biopsy in HAE type I. Icatibant has also reportedly been used for type III HAE, although it is not licensed for this indication. The objective of this report is to review the therapeutic and prophylactic effectiveness and harms of icatibant in the treatment of type III HAE. |
|---|---|
| Item Description: | Title from PDF caption |
| Physical Description: | 1 PDF file (10 pages) illustration |